

**Department of Oncology
2013 Publications**

Bassam Abdulkarim

1. Lesniak D, **Sabri S**, Xu Y, Graham K, Bhatnagar P, Suresh M, **Abdulkarim B**. Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer. *PLoS One*. 2013 Aug 26;8(8):e71987. doi: 10.1371/journal.pone.0071987. eCollection 2013.
2. Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, **Abdulkarim B**. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. *Radiat Oncol*. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

Sharon Abish

1. Essa M, Santo AE, Fleming A, Mitchell D, **Abish S**. Exploring the Attitudes of Pediatric Oncologists Toward the Use of Laxatives for the Prevention of Constipation in Patients Undergoing Active Treatment: A Canadian Perspective. *Pediatr Hematol Oncol*. 2013 Oct 2. [Epub ahead of print]
2. Siminoski K, Lee KC, **Abish S**, Alos N, Bell L, Blydt-Hansen T, Couch R, Cummings EA, Ellsworth J, Feber J, Fernandez CV, Halton J, Huber AM, Israels S, Jurencak R, Lang B, Laverdière C, LeBlanc C, Lewis V, Midgley J, Miettunen PM, Oen K, Phan V, Pinsk M, Rauch F, Rodd C, Roth J, Saint-Cyr C, Scuccimarri R, Stephure D, Taback S, Wilson B, Ward LM; Canadian STOPP Consortium National Pediatric Bone Health Working Group. The development of bone mineral lateralization in the arms. *Osteoporos Int*. 2013 Mar;24(3):999-1006. doi: 10.1007/s00198-012-2054-2. Epub 2012 Jun 29.

Moulay Alaoui-Jamali

1. Silva SD, **Alaoui-Jamali MA**, Soares FA, Carraro DM, Brentani HP, **Hier M**, Rogatto SR, Kowalski LP. TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. *Cancer*;120(3):352-62, 2014 (Co-corresponding author)
2. Silva SD, **Alaoui-Jamali MA**, **Hier M**, Soares FA, Graner E, Kowalski LP. Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread. *Clin Exp Metastasis*. 31(3):307-16, 2014.
3. Xu B, Teng LH, Silva SD, Bijian K, Al Bashir S, Jie S, Dolph M, **Alaoui-Jamali MA**, Bismar TA. The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. *Cancer Med*. 2013 Dec 18. (Co-corresponding author)
4. Bijian K, Loughheed C, Su J, Xu B, Yu H, **Wu JH**, Riccio K, **Alaoui-Jamali MA**. Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine. *Br J Cancer*;109(11):2810-8, 2013.

**Department of Oncology
2013 Publications**

5. Garcia AG, Nedev H, Bijian K, Su J, **Alaoui-Jamali MA**, Saragovi HU. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs. *Oncogene*. 2013;16;32:2527-33, 2013.

Thierry Alcindor

1. Ringash J, Au HJ, Shapiro JD, Jonker DJ, Zalcborg JR, Moore MJ, Strickland A, Kotb RR, Jeffery M, **Alcindor T**, Ng S, Salim M, Sabesan S, Easaw J, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ. Quality of life in K-RAS WT colorectal cancer: the CO.20 phase III randomized trial. *Cancer*. 2013 Oct 11. doi: 10.1002/cncr.28410. [Epub ahead of print]
2. Madani A, Spicer J, **Alcindor T, David M, Vanhuyse M, Asselah J, Mulder D, Ferri L**. Clinical Significance Of Incidental Pulmonary Nodules In Esophageal Cancer Patients. *Journal of Gastrointestinal Surgery*. 2013 September 4. [Epub ahead of print]
3. Diaz Z , Aguilar-Mahecha A, Paquet ER , **Basik M** , Orain M, Camlioglu E, Constantin E, Benlimame N, Bachvarov D, Jannot G, Simard MJ, Chabot B, A. Gologan A, Klinck R, Gagnon-Kugler T, B. Lespérance B, Samson B, **Kavan P, Alcindor T, Dalfen R**, Metrakos P, Lan C, Chabot C, Buchanan M, Przybytkowski E, Qureshi S, Rousseau C, **Spatz A**, Têtu B, **Batist G**. Next-generation biobanking of liver metastatic biopsies to enable multidimensional molecular profiling. *Modern Pathology*. 2013 Jun 7. doi: 10.1038/modpathol.2013.81. [Epub ahead of print]
4. Demetri G, Chawla S, Ray-Coquard I, Le Cesne A, Staddon A, Milhem M, Penel N, Riedel R, Bui-Nguyen B, Cranmer L, Reichardt P, Bompas E, **Alcindor T**, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid J, Loewy J, Haluska F, Dodion P, Blay JY. Results of an international randomized phase 3 trial of the mTOR inhibitor, ridaforolimus, versus placebo to control metastatic sarcomas in patients following benefit from prior chemotherapy. *Journal of Clinical Oncology*. 2013 May 28. [Epub ahead of print]
5. *Moreau LC, **Rajan R, Thirlwell MP, Alcindor T**. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. *Anticancer Research*. 2013 Apr;33(4):1765-8.
6. **Alcindor T, Ferri LE**, Marcus V, Andalib A, Hickeson M, Artho G, Chasen M, **Thirlwell MP**, Ades S. Perioperative DCF Chemotherapy Protocol for Patients with Gastroesophageal Adenocarcinoma: Correlation between Response to Treatment and Outcome. *Medical Oncology*. 2013 Mar; 30(1):377. doi: 10.1007
7. *Garg A, Nahal A, **Turcotte R, Tabah R, Alcindor T**. Primitive neuroectodermal tumor (PNET) as somatic-type malignancy arising from an extragonadal germ cell tumor: clinical, pathological and molecular features of a case. *Tumori*. 2013 Jan-Feb;99(1):24e-7e. doi: 10.1700/1248.13807.

**Department of Oncology
2013 Publications**

Jamil Asselah

1. Madani A, Spicer J, **Alcindor T, David M, Vanhuyse M, Asselah J, Mulder D, Ferri L.** Clinical Significance of Incidental Pulmonary Nodules in Esophageal Cancer Patients. *J Gastrointest Surg.* 2013 Sep 4
2. Saad F, **Asselah J.** Chemotherapy for prostate cancer: Clinical practice in Canada. *Can Urol Assoc J.* 2013 Jan;7(2 Suppl 1):S5-S10.
3. **Asselah J,** Sperlich C. Post-docetaxel options for further survival benefit in metastatic Castration-resistant prostate cancer: Questions of choice. *Can Urol Assoc J.* 2013 Jan;7(2 Suppl 1):S11-7

Sarit Assouline

1. Shawi M, Chu TW, Martinez-Marignac V, Yu Y, Gryaznov SM, Johnston JB, Lees-Miller SP, **Assouline SE,** Autexier C, **Aloyz R.** Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes. *PLoS One.* 2013 Jul 29;8(7):e70428. doi: 10.1371/journal.pone.0070428.
2. Palumbo MO, **Kavan P, Miller WH Jr, Panasci L, Assouline S, Johnson N, Cohen V, Patenaude F, Pollak M, Jagoe RT, Batist G.** Systemic cancer therapy: achievements and challenges that lie ahead. *Front Pharmacol.* 2013 May 7;4:57. doi: 10.3389/fphar.2013.00057. eCollection 2013.
3. Nielsen TH, **Johnson N,** Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, **Assouline S, Miller WH Jr, Mann KK.** Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. *Front Pharmacol.* 2013 Feb
4. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, **Assouline S,** Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. *J Clin Oncol.* 2013 Feb 20;31(6):676-83. doi: 10.1200/JCO.2012.46.2309. Epub 2012 Nov 19.
5. Macdonald DA, **Assouline SE,** Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Caplan S, Foo A, Walsh W, Leber B. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. *Leuk Lymphoma.* 2013 Apr;54(4):760-6. doi: 10.3109/10428194.2012.737917. Epub 2012 Nov 15.

**Department of Oncology
2013 Publications**

Laurent Azoulay

1. **Azoulay L**, Dell'Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. *Eur Heart J* 2013 (available online ahead of print).
2. Chukkapalli S, Amessou M, Dilly AK, Dekhil H, Zhao J, Liu Q, Bejna A, Thomas RD, Bandyopadhyay S, Bismar TA, Neill D, **Azoulay L**, **Batist G**, Kandouz M. Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. *Exp Cell Res* 2013;S0014-4827(13)00472-2.
3. Yu O*, Eberg M, Benayoun S, **Aprikian A**, **Batist G**, Suissa S, **Azoulay L**. Use of Statins and the Risk of Death in Patients With Prostate Cancer. *J Clin Oncol* 2013 [available online ahead of print]
4. Smiechowski B, **Azoulay L**, Yin H, **Pollak MN**, Suissa S. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. *Cancer Epidemiol Biomarkers Prev* 2013;22(10):1877-83.
5. Lapi F, **Azoulay L**, **Niazi MT**, Yin H, Benayoun S, Suissa S. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. *JAMA* 2013;310(3):289-296.
6. Assayag J*, Yin H, Benayoun S, **Pollak MN**, Suissa S, **Azoulay L**. Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer. *Cancer Causes Control* 2013;24:839-845.
7. Poulin-Costello M, **Azoulay L**, Van CE, Peeters M, Siena S, Wolf M. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. *Target Oncol* 2013;8(2):127-36.
8. Smiechowski BB, **Azoulay L**, Yin H, **Pollak MN**, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. *Diabetes Care* 2013;36:124-129.
9. Lapi F, **Azoulay L**, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. *BMJ* 2013;346:e8525.
10. **Azoulay L**, Dell'aniello S, Simon T, Renoux C, Suissa S. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. *Thromb Haemost* 2013;109(3):431-439.

Gerald Batist

1. Puts M, Monette J, Girre V, Sourial N, Wolfson C, Monette M, **Batist G**, Bergman H. The relationship of self-rated health with functional status, toxicity and mortality: results of a

**Department of Oncology
2013 Publications**

- prospective pilot study of older patients with newly-diagnosed cancer. *J Geriatr Oncol.* 2013 Oct;4(4):319-26. doi: 10.1016/j.jgo.2013.07.003. Epub 2013 Aug 12.
2. Butts C, Kamel-Reid S, **Batist G**, Chia S, Blanke C, Moore M, Sawyer MB, Desjardins C, Dubois A, Pun J, Bonter K, Ashbury FD. Benefits, issues, and recommendations for personalized medicine in oncology in Canada. *Curr Oncol.* 2013 Oct;20(5):e475-83. doi: 10.3747/co.20.1253.
 3. **Bouganim N**, Mamo A, Wasserman DW, **Batist G**, Metrakos P, **Chaudhury P**, Hassanain M, **Kavan P**. Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. *Curr Oncol.* 2013 Oct;20(5):247-51. doi: 10.3747/co.20.1370.
 4. **Basik M**, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, **Spatz A**, **Greenwood CM**, **Batist G**. Biopsies: next-generation biospecimens for tailoring therapy. *Nat Rev Clin Oncol.* 2013 Aug;10(8):437-50. doi: 10.1038/nrclinonc.2013.101. Epub 2013 Jun 25. Review. Erratum in: *Nat Rev Clin Oncol.* 2013 Nov;10(11):608.
 5. Diaz Z, Aguilar-Mahecha A, Paquet ER, **Basik M**, Orain M, Camlioglu E, Constantin A, Benlimame N, Bachvarov D, Jannot G, Simard MJ, Chabot B, Gologan A, Klinck R, Gagnon-Kugler T, Lespérance B, Samson B, **Kavan P**, **Alcindor T**, Dalfen R, Lan C, Chabot C, Buchanan M, Przybytkowski E, Qureshi S, Rousseau C, **Spatz A**, Têtu B, **Batist G**. Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. *Mod Pathol.* 2013 Nov;26(11):1413-24. doi: 10.1038/modpathol.2013.81. Epub 2013 Jun 7.
 6. Palumbo MO, **Kavan P**, **Miller WH Jr**, **Panasci L**, **Assouline S**, **Johnson N**, **Cohen V**, **Patenaude F**, **Pollak M**, **Jagoe RT**, **Batist G**. Systemic cancer therapy: achievements and challenges that lie ahead. *Front Pharmacol.* 2013 May 7;4:57. doi: 10.3389/fphar.2013.00057. eCollection 2013.
 7. Mamo A, Nogueira MC, **Batist G**, Palumbo M, **Panasci L**, **Ferrario C**, **Chaudhury P**, Metrakos P, **Kavan P**. A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. *Curr Oncol.* 2013 Apr;20(2):e107-12. doi: 10.3747/co.20.1271.
 8. Kandouz M, Zhao J, Bier A, Di Marco S, Oviedo-Landaverde I, Gallouzi IE, **Batist G**. Post-transcriptional regulation of connexin43 in H-Ras-transformed cells. *PLoS One.* 2013;8(3):e58500. doi: 10.1371/journal.pone.0058500. Epub 2013 Mar 11.
 9. Black L, **Batist G**, Avard D, Rousseau C, Diaz Z, Knoppers BM. Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited. *Front Pharmacol.* 2013 Mar 11;4:25. doi: 10.3389/fphar.2013.00025. eCollection 2013.
 10. **Körner A**, Drapeau M, Thombs BD, **Rosberger Z**, **Wang B**, Khanna M, **Spatz A**, Coroiu A, Garland R, **Batist G**. Barriers and facilitators of adherence to medical advice on skin self-

**Department of Oncology
2013 Publications**

examination during melanoma follow-up care. *BMC Dermatol.* 2013 Mar 1;13:3. doi: 10.1186/1471-5945-13-3.

11. Gottlieb B, Alvarado C, Wang C, Gharizadeh B, Babrzadeh F, Richards B, **Batist G, Basik M**, Beitel LK, Trifiro M. Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues. *Hum Mutat.* 2013 Apr;34(4):610-8. doi: 10.1002/humu.22287. Epub 2013 Mar 8.
12. **Wu JH, Batist G.** Glutathione and glutathione analogues; therapeutic potentials. *Biochim Biophys Acta.* 2013 May;1830(5):3350-3. doi: 10.1016/j.bbagen.2012.11.016. Epub 2012 Nov 28. Review.

Nicole Beauchemin

1. Arabzadeh*, C. Chan*, A.L. Nouvion*, S. Benlolo*, L. DeMarte*, C. Turbide*, **P. Brodt**, L. Ferri and **N. Beauchemin**. Host-Related Carcinoembryonic Antigen Cell Adhesion Molecule 1 Promotes Metastasis of Colorectal Cancer. *Oncogene* 32(7):849-60 (2013).
2. Meunier*, L. Van Der Kraak*, C. Turbide*, N. Groulx, P. Cingolani, M. Blanchette, G. Yeretssian, M. Saleh, **N. Beauchemin** and P. Gros. *Nfkb1* as a Positional Candidate for The Mouse *Ccs3* Locus that Regulates Differential Susceptibility To Carcinogen-Induced Colorectal Cancer. *PlosOne* 8(3): e58733(2013).
3. S. Hosomi, Z. Chen, K. Baker, L. Chen, Y.-H. Huang, T. Olszak, S. Zeissig, J. H. Wang, O. Mandelboim, **N. Beauchemin**, L. L. Lanier, R. S. Blumberg. CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling. *Eur. J. Immunol.*43 (9): 2473-83 (2013); doi: 10.1002/eji.201242676.
4. S.M. Najjar, K. J. Ledford, S. L. Abdallah, A. Paus, L. Russo, M. K. Kaw, S. K. Ramakrishnan, H. T. Muturi, C. K. Raphael, S. Ghosh-Lester, G. Heinrich, S. V. Pierre, R. Benndorf, V. Kleff, A. A. Jaffa, E. Lévy, G. Vazquez, I.J. Goldberg, **N. Beauchemin**, R. Scalia, and S. Ergün. *Ceacam1* Null Deletion Causes Aortic Vascular Alterations. *Am. J. Physiology - Endocrinology and Metabolism* 305 (4): E519-29 (2013); doi: 10.1152/ajpendo.00266.2013.
5. **N. Beauchemin** and A. Arabzadeh*. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. *Cancer Metastasis Rev.* 32(3-4): 643-71 (2013); doi: 10.1007/s10555-013-9444-6.

Nathaniel Bouganim

1. Dranitsaris G, **Bouganim N**, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M. Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. *J Support Oncol.* 2013 Mar;11(1):14-21.
2. **Bouganim N**, Mamo A, Wasserman DW, **Batist G**, Metrakos P, **Chaudhury P**, Hassanain M, **Kavan P**. Bevacizumab-based therapy for colorectal cancer: experience from a large

**Department of Oncology
2013 Publications**

Canadian cohort at the Jewish General Hospital between 2004 and 2009. *Curr Oncol.* 2013 Oct;20(5):247-51. doi: 10.3747/co.20.1370.

S. Robin Cohen

1. Heyland, DK, Jiang X, Day AG, **Cohen SR**. The Development and Validation of a Shorter Version of the Canadian Health Care Evaluation Project Questionnaire (CANHELP Lite): A novel tool to measure of Patient and Family Satisfaction with End of Life Care. *J Pain Symptom Manage.* 2013; 46:289-297. <http://dx.doi.org/10.1016/j.jpainsymman.2012.07.012>
2. *MacKinnon CJ, Millman E, Smith NG, **Henry M**, Berish M, Copeland L, **Körner A**, Chochinov HM, **Cohen SR**. Means to Meaning in Cancer-Related Bereavement: Clinical Implications for Counseling Psychologists. *The Counseling Psychologist.* 2013 Feb; 41(2):216-239. doi: 10.1177/0011000012459969
3. Kogan NR, Dumas M, **Cohen SR**. The extra burdens patients in denial impose on their family caregivers. *J Palliat Supp Care.* 2013 Apr; 11(2):91-99. doi:10.1017/S1478951512000491.

Fabio Cury

1. **Cury FL**, Hunt D, Roach M 3rd, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. *Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413.* *Cancer.* 2013 Jun 1;119(11):1999-2004.
2. Rodrigues G, Lukka H, Warde P, Brundage M, **Souhami L**, Crook J, **Cury F**, Catton C, Mok G, Martin AG, Vigneault E, Morris J, Warner A, Gonzalez Maldonado S, Pickles T; *The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis.* Genitourinary Radiation Oncologists of Canada (GUROC). *Radiother Oncol.* 2013 Nov
3. Nassim R, Mansure JJ, Chevalier S, **Cury F**, Kassouf W. *Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment.* *PLoS One.* 2013 Jun 17;8(6).
4. Chevalier S, **Cury FL**, Scarlata E, El-Zayat E, Hamel L, Rocha J, Zouanat FZ, Moussa S, Scherz A, Elhilali M, Anidjar M. *Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.* *J Urol.* 2013 Nov;190(5):1946-53.
5. Patel N, **Faria S**, **Cury F**, **David M**, **Duclos M**, **Shenouda G**, Ruo R, **Souhami L**. *Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.* *Int J Radiat Oncol Biol Phys.* 2013 Jul 1;86(3):534-9.

**Department of Oncology
2013 Publications**

6. Textbook “Experimental and Clinical Metastasis. A Comprehensive Review”. Burnier, Julia.; Burnier, Miguel N (Eds.) 2013, XVI, 472 p. Contribution: chapter “Palliative Radiation Therapy”. **F. Cury** and **G. Shenouda**.
7. Textbook “Radioterapia Em Oncologia”. Salvajoli, J.V.; **Faria, S.; Souhami L.** (Eds.). Editora: Atheneu. 1320 p. Contribution: chapter “Skin Cancer – Melanoma”. **F. Cury**
Contribution: chapter “Skin Cancer – Non-Melanoma”. **F. Cury**
Contribution: chapter “Hypopharyngeal Cancer”. **F. Cury**
Contribution: chapter “Penile Cancer”. **F. Cury** and E. Roesler.
Contribution: chapter “Kidney Cancer”. N. Rene and **F. Cury**.

Slobodan Devic

1. S. Aldelaijan, A. Nobah, G Alsbeih, B. Mofteh, I. Aldahlawi, A. Alzahrany, N. Tomic and **S. Devic**, “Dosimetry of biological irradiations using radiochromic films,” *Physics in Medicine and Biology* **58**, 3177-3189 (2013).
2. Webster MJ, **Devic S, Vuong T**, Han D, Park J Custin, Scanderbeg D, Lawson J, Einck J, Jia X, Pawlicki, Bongyong Song T, Watkins WT, Song WY. Dynamic Modulated Brachytherapy (DMBT) for rectal cancer. *Medical Physics*, Volume 40, Issue 1, Pages 011718-1- 011718-2, January 2013
3. Webster M, **Devic S, Vuong T**, Scanderbeg D, Han D, Song W. HDR Brachytherapy of Rectal Cancer Using a Novel Grooved-Shielding Applicator Design, *Medical Physics*, Volume 40, No. 9, September 2013
4. **S. L. Faria, S. Devic**, Chapter 37: “PET em Radioterapia,” in Salvajoli JV, Souhami L e Faria SL. "RADIOTERAPIA EM ONCOLOGIA", 2nd Edition, Ed. Atheneum, Rio de Janeiro, 2013, p1219-1224.

Vanessa Dumeaux

1. Ritte R, Tikk K, Lukanova A, Tjønneland A, Olsen A, Overvad K, Dossus L, Fournier A, Clavel-Chapelon F, Grote V, Boeing H, Aleksandrova K, Trichopoulou A, Laggiou P, Trichopoulos D, Palli D, Berrino F, Mattiello A, Tumino R, Sacerdote C, Quirós JR, Buckland G, Molina-Monte E, Chirlaque MD, Ardanaz E, Amiano P, Bueno-de-Mesquita HB, van Gils CH, Peeters PHM, Wareham N, Khaw KT, Key TJ, Travis RC, Weiderpass E, **Dumeaux V**, Lund E, Sund M, Andersson A, Romieu I, Rinaldi S, Vineis P, Merritt MA, Riboli E and Kaaks R. *Reproductive factors and risk of hormone receptor positive and negative breast cancer: A cohort study.* *BMC Cancer* 2013;13:584.
2. Landmark-Høyvik H, **Dumeaux V**, Nebdal D, Lund E, Tost J, Kamatani Y, Renault V, Børresen-Dale AL, Kristensen V, Edvardsen H. *Genome-wide association study in breast cancer survivors reveals SNPs associated with gene expression of genes belonging to MHC class I and II.* *Genomics* 2013;102:278-87.

**Department of Oncology
2013 Publications**

Issam El Naqa

1. C. Robinson, T. DeWees, **I. El Naqa**, K. Creach, J. Olsen, T. Crabtree, B. Meyers*, V. Puri, P. Parikh, J. Bradley, "Patterns of Failure and Survival after Stereotactic Body Radiation Therapy or Lobar Resection for Clinical Stage I Non-small-cell Lung Cancer," *Journal of Thoracic Oncology (JTO)*, 2013 Feb;8(2):192-201

Michael Evans

1. S. Quinlan-Davidson, T. AlMahmoud, R. Al-Wassia, **MDC Evans**, G. Ph.D, S. Callejo, C. Edelstein, **G. Shenouda**: Intraoperative sonographically assisted radioactive iodine 125 plaque brachytherapy for choroidal melanoma: visual acuity outcome. *J. Ultrasound Med.*, Jun;32(6):995-1001, 2013.
2. S. Davis, **W. Parker, M. Evans**; Using integral activity to compare relative dosimetric efficiency with respect to source type and source change schedules for HDR brachytherapy.: *Journal of Applied Clinical Medical Physics*, Vol 14 (6), pp 53-61, 2013.

Marc Fabian

1. **Fabian, M.R. (co-corresponding author)**, Frank, F., Rouya, C., Siddiqui, N., Lai, W.S., Karetnikov, A., Blackshear, P.J., Nagar, B. and Sonenberg, N. (2013) Structural basis for the recruitment of the CCR4-NOT deadenylase complex by Tristetraprolin. *Nature Structural and Molecular Biology* 20(6):735-9.
2. Svitkin, Y.V., Yanagiya, A., Karetnikov, A., Alain, T., **Fabian, M.R.**, Khoutorsky, A., Perreault, S., **Topisirovic, I.** and Sonenberg, N. (2013) Control of Translation and miRNA-Dependent Repression by a Novel Poly(A) Binding Protein, hnRNP-Q. *PLOS Biology* 11(5):e1001564.
3. Khoutorsky, A., Yanagiya, A., Gkogkas, C, **Fabian, M.R.**, Prager-Khoutorsky, M., Cao, R., Gamache, K., Bouthiette, F., Parsyan, A., Sorge, R.E., Mogil, J., Nader, K., Lacaille, J-C. and Sonenberg, N. (2013) Control of synaptic plasticity and memory via suppression of poly(A)-binding protein. *Neuron* 78(2):298-311.

Sergio Faria

1. N. Patel, **S. Faria, F. Cury, M. David, M. Duclos, G. Shenouda**, R. Ruo, and **L. Souhami**. Hypofractionated radiotherapy (66 Gy in 22 fractions at 3 Gy per fraction) for favourable risk prostate cancer: long term outcomes. *Int J Radiat Oncol Biol Phys*. 2013 Jul 1;86(3):534-9
2. Daniel M. Bernad, Alan Dal Pra, Cintia Baule, Benicio N. Frey, **Sergio Faria**. New-Onset Psychosis Following Androgen Deprivation Therapy For Prostate Cancer. *Can J Urol*. 2013 Aug;20(4):6868-70
3. **Sergio Faria, Neil Kopek, Tarek Hijal, Sender Liberman**, Patrick Charlebois, **Barry Stein, Sarkis Meterissian, Ari Meguerditchian**, Ziad Fawaz, Giovanni Artho. Phase II trial of short-course radiotherapy alone followed by delayed surgery for locally advanced rectal cancer. *Colorectal Dis*. 2013, Oct 22. doi: 10.1111/codi.12466. [Epub ahead of print]

**Department of Oncology
2013 Publications**

Cristiano Ferrario

1. Mamo A, Nogueira MC, **Batist G**, Palumbo M, **Panasci L**, **Ferrario C**, **Chaudhury P**, Metrakos P, **Kavan P**. A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. *Curr Oncol*, 2013; 20:e107-12.
2. Dery MA, Jodoin J, **Ursini-Siegel J**, Aleynikova O, **Ferrario C**, Hassan S, **Basik M**, Leblanc AC. Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer. *Breast Cancer Res*, 2013; 15: R22.
3. Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, **Ferrario C**, Fedeli A, Faedi M, Nanni O, Frassinetti GL, Amadori D, Rocca A. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and predictive factors. *Heart*, 2013; 99: 634-9.

Eduardo Franco

1. CHEVARIE-DAVIS M(§), **RAMANAKUMAR AV**, FERREIRA S, FERENCZY A, VILLA LL, **FRANCO EL(*)**, FOR THE LUDWIG-MCGILL COHORT STUDY. Assessment of the performance of algorithms for cervical cancer screening: Evidence from the Ludwig-McGill Cohort Study. *Gynecologic Oncology* 128: 415-419, 2013.
2. FORMENTIN A, ARCHAMBAULT J, KOUSHIK A, RICHARDSON H, BRASSARD P, **FRANCO EL**, COUTLEE F(*). Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix. *International Journal of Cancer* 132: 1821-1830, 2013.
3. WALTER SD(*), RIDDELL CA, RABACHINI T, VILLA LL, **FRANCO EL**. Accuracy of p53 codon 72 polymorphism status determined by multiple laboratory methods: a latent class model analysis. *PLoS-One* 8(2):e56430.
4. TOTA JE(§), **RAMANAKUMAR AV**, MAHMUD SM., TREVISAN A, VILLA LL, **FRANCO EL(*)**, FOR THE LUDWIG-MCGILL COHORT STUDY GROUP. Cervical Human Papillomavirus Detection is Not Affected by Menstrual Phase. *Sexually Transmitted Infections* 89: 202-206, 2013.
5. ANDALIB A(§), **RAMANA-KUMAR AV**, BARTLETT G, **FRANCO EL**, **FERRI LE(*)**. Influence of postoperative infectious complications on long-term survival of lung cancer patients: a population-based cohort study. *Journal of Thoracic Oncology* 8: 554-561, 2013.
6. CERIGO H, COUTLEE F, **FRANCO EL**, BRASSARD P(*). Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada. *Biomed Central Public Health*, 13:438, 2013.
7. ROSITCH AF(*), KOSHIOL J, HUDGENS MG, RAZZAGHI H, BACKES DM, PIMENTA JM, **FRANCO EL**, POOLE C, SMITH JS. Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis. *International Journal of Cancer* 133: 1271-1285, 2013.

**Department of Oncology
2013 Publications**

8. DROLET M, BOILY MC, VAN DE VELDE N, **FRANCO EL**, BRISSON M(*). Vaccinating girls and boys with different human papillomavirus vaccines: Can it optimise population-level effectiveness? PLoS-One 8(6):e67072.
9. TREVISAN A(§*), SCHLECHT NF, **RAMANAKUMAR AV**, VILLA LL, **FRANCO EL**, Ludwig-McGill Study Group. HPV16 viral load measurement as a predictor of infection clearance. Journal of General Virology 94: 1850-1857, 2013.
10. OLIVEIRA LB, LOUVANTO K, **RAMANAKUMAR AV**, **FRANCO EL**, VILLA LL(*), for the Ludwig-McGill Cohort Study. Polymorphism in the promoter region of the Toll-Like Receptor 9 gene and cervical human papillomavirus infection. Journal of General Virology 94: 1858-1864. 2013.
11. METCALFE S, ROGER M, FAUCHER MC, COUPLÉE F, **FRANCO EL**, BRASSARD P(*). The frequency of HLA alleles in a population of Inuit women of northern Quebec. International Journal of Circumpolar Health 72: 21350, 2013. DOI: 10.3402/ijch.v72i0.21350 .
12. TOTA J(§), **RAMANA-KUMAR AV**, JIANG M, DILLNER J, WALTER SD, KAUFMAN JS, COUPLÉE F, VILLA LL, **FRANCO EL**(*). Epidemiological Approach to Evaluate the Potential for Human Papillomavirus Type Replacement Post-vaccination. American Journal of Epidemiology 178: 625-634, 2013.
13. BRISSON M(*), LAPRISE JF, DROLET M, VAN DE VELDE N, **FRANCO EL**, KLIEWER EV, OGILVIE G, DEEKS SL, BOILY MC. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. Vaccine 31: 3863-3871, 2013.
14. ISIDEAN SD(§), **FRANCO EL**(*). Counterpoint: Cervical Cancer Screening Guidelines: Approaching the Golden Age. American Journal of Epidemiology 178: 1023-1026, 2013.
15. OGILVIE GS(*), SMITH LW, VAN NIEKERK DJ, KHURSHED F, KRAJDEN M, SARAIYA M, GOEL V, RIMER B BK, GREENE SB, HOBBS S, COLDMAN AJ, **FRANCO EL**. Women's intentions to receive cervical cancer screening with primary human papillomavirus testing. International Journal of Cancer 133 :2934-2943, 2013.
16. BOSCH FX(*), BROKER TR, FORMAN D, MOSCICKI AB, GILLISON ML, DOORBAR J, STERN PL, STANLEY M, ARBYN M, POLJAK M, CUZICK J, CASTLE PE, SCHILLER JT, MARKOWITZ LE, FISHER WA, CANFELL K, DENNY LA, **FRANCO EL**, STEBEN M, KANE MA, SCHIFFMAN M, MEIJER CJLM, SANKARANARAYANAN R, CASTELLSAGUÉ X, KIM JJ, BROTONS M, ALEMANY L, ALBERO G, DIAZ M, SANJOSÉ S, for the authors of the ICO Monograph. Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine 31S: I1-I31, 2013.
17. TOMITA LY, D' ALMEIDA V, VILLA LL, **FRANCO EL**, CARDOSO MA(*), FOR THE BRINCA STUDY GROUP. Polymorphisms in genes involved in folate metabolism modify the

**Department of Oncology
2013 Publications**

association of dietary and circulating folate and vitamin B-6 with cervical neoplasia. Journal of Nutrition 143 : 2007-2014, 2013.

18. METCALFE S, ROGER M, FAUCHER MC, COUtlÉE F, **FRANCO EL**, BRASSARD P(*). The association between human leukocyte antigen (HLA)-G polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec. Human Immunology 74: 1610-1615, 2013.
19. RODRIGUES-COULtÉE C, ARCHAMBAULT J, MONEY D, **RAMANAKUMAR AV**, RABOUD J, HANKINS C, KOUSHIK A, RICHARDSON H, BRASSARD P, **FRANCO EL**, COUtlÉE F(*), CANADIAN WOMEN'S HIV STUDY GROUP. Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions. Journal of Clinical Virology 58 : 660-665, 2013.
20. **FRANCO EL**. Preventive medicine: new editorial office but the same vision. Preventive Medicine 56: 1-2, 2013.
21. **ROSBERGER Z**(*), PEREZ S, KING L, **FRANCO EL**. Public perception: A significant challenge in the battle against HPV. Oncology Exchange 12: 16-20, 2013.
22. BRISSON M(*), DROLET M, BOILY MC, MALAGÓN T, **FRANCO EL**, LAPRISE J, VAN DE VELDE N, MAYRAND MH, KLIEWER EV, COUtlÉE F. Letter re: population-level impact of the bivalent, quadrivalent, and candidate nonavalent human papillomavirus vaccines: a comparative model-based analysis. Journal of the National Cancer Institute 105: 664-665, 2013.
23. **FRANCO EL**, **SHINDER GA**. Combatting obesity - A helping hand from the business community. Preventive Medicine 57: 251-252, 2013.

Carolyn Freeman

1. Vakilian S, **Freeman CR**, Al-Suhaibani A, Roberge D. Kinetics of myxoid liposarcoma radiation response and effects on radiation dose delivery. Practical Radiation Oncology 2013; 3:180-185
2. Roberge D, Vakilian S, Alabed Y, **Turcotte R**, **Freeman CR**, Hickeson M. *FDG-PET/CT in initial staging of adult soft-tissue sarcoma*. Sarcoma 2012;
3. Al Wassia R, Bahig H, Poon E, **Parker W**, **Freeman C**. Daily set-up uncertainty for craniospinal irradiation using helical tomotherapy. Practical Radiation Oncology 2013; 3:349-355
4. Bahig H, Roberge D, Bosch W, Levin W, Petersen I, Haddock M, **Freeman C**, DeLaney T, Abrams R, Indelicato D, Baldini E, Hitchcock Y, Kirsh DG, Kozak KR, Wolfson A, Wang D. Agreement among RTOG sarcoma radiation oncologists in contouring suspicious peritumoral edema for preoperative radiation therapy of soft tissue sarcoma of the extremity. International Journal of Radiation Oncology Biology and Physics 2013; 86:298-303

**Department of Oncology
2013 Publications**

5. Charpentier A-M, **Freeman C**, Roberge D, Rousseau P. Radiotherapy. In Pediatric Neuro-oncology. Springer. Chapter 18, 2013.

Walter Gotlieb

1. Drudi L, Press J, **Lau S**, Gotlieb S, How S, Drummond N, Brin S, Deland S, **Gotlieb W**, vaginal vault dehiscence after robotic hysterectomy in patients with gynecologic cancers: Prospective evaluation and literature review. *Int J Gynecol Cancer* (2013) 23: 943-50
2. Niu X, Rajanbabu A, Delisle M, Peng F, Vijaykumar DK, Pavithran K, Feng Y, **Lau S**, **Gotlieb WH**, Press J. Brain metastases in women with epithelial ovarian cancer: multimodal treatment including surgery or gamma-knife radiation is associated with prolonged survival. *J Obstet Gynaecol Can* (2013) 35:816-22
3. Alzahrani T, Haddad R, Alkhayal A, Delisle J, Drudi L, **Gotlieb W**, Fraser S, Bergman S, **Bladou F**, Andonian S, Anidjar M. Validation of the da Vinci Surgical Skill Simulator across three surgical disciplines. *Can Urol Assoc J.* (2013) 7: E520-9
4. Zhang J, Shi Y, Lalonde E, Li L, Cavalione L, Ferenczy A, **Gotlieb WH**, **Foulkes WD**, Majewski J. Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient *BMC Cancer* (2013) 13:146
5. Lavoue V, **Lau S**, Press J, Abitbol J, Zeng X, Gotlieb R, How J, Wang Y, **Gotlieb WH** Bénéfices de la chirurgie robotique pour les patientes âgées avec un cancer de l'endomètre. *MSAmerique* (2013) 2:19-36

Celia Greenwood

1. Dastani Z, Johnson T, Kronenberg F, Nelson CP, Assimes TL, März W; CARDIoGRAM Consortium; ADIPOGen Consortium, Richards JB (2013). The shared allelic architecture of adiponectin levels and coronary artery disease. *Atherosclerosis* 229(1):145-8.
2. M Ladouceur, **CMT Greenwood**, JB Richards, HF Zheng (2013). Empirical Power of Very Rare Variants for Common Traits and Disease: Results from Sanger Sequencing 1,998 Individuals. *European Journal of Human Genetics* 21(9): 1027-30.
3. K Klein Oros, SL Arcand, JA Squire, A-M Mes-Masson, **PN Tonin**, **CMT Greenwood** (2013). Analysis of genomic abnormalities in tumours: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. *Cancer Genetics* 206(4): 103-115.
4. Oualkacha, K., Dastani, Z., Li, R., Cingolani, P. E., Spector, T. D., Hammond, C. J., Richards, J. B., Ciampi, A. and **Greenwood, CMT** (2013). Adjusted Sequence Kernel Association Test for Rare Variants Controlling for Cryptic and Family Relatedness. *Genet. Epidemiol.* 37: 366-376. doi: 10.1002/gepi.21725.

**Department of Oncology
2013 Publications**

5. Chen Z, **Greenwood C**, Isaacs WB, **Foulkes WD**, Sun J, Zheng SL, Condreay LD, Xu J (2013). The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: Results from the REDUCE trial. *Carcinogenesis* 34(6): 1260-4.
6. **Mark Basik**, Adriana Aguilar-Mahecha, Caroline Rousseau, Zuanel Diaz, Sabine Tejpar, **Alan Spatz**, **Celia M.T. Greenwood**, and Gerald Batist. (2013) Metastatic biopsies – next-generation biospecimens. *Nature Reviews Clinical Oncology* 10(8): 437-450.
7. W Xu, SB Bull, L Mirea, **CM Greenwood** (2013). Model-free linkage analysis of a binary trait. *Methods in Molecular Biology*: 850: 317-345. *Statistical Human Genetics*. Editors: Robert C. Elston, Jaya Satagopan, Shuying Sun. Humana Press.
8. SB Bull, J Graham, **CM Greenwood**. (2013) Statistical Genetic Modeling and Analysis of Complex Traits in Human Populations. *Statistical Science in Canada* Editor: Jerry Lawless. Statistical Society of Canada (in press 31 March 2013).
9. **CMT Greenwood**, C Xu, A Ciampi. Significance thresholds for rare variant signals. Submitted March 2013. *Assessing rare variation in complex traits: design and analysis of genetic studies*. Editors: Andrew Morris, Eleftheria Zeggini. Springer.
10. *Epigenetics and Complex Traits* (Published September 2013). Editors: AK Naumova, **CMT Greenwood**. Springer, New York.

Michael Hier

1. Sabrina Daniela Silva, Faisal A. Alobaid, **Moulay Alaoui-Jamali**, **Michael P. Hier**, Alex Mlynarek, Fernando Augusto Soares, Luis Paulo Kowalski. PP022: EMT-associated genes are predictive markers in multiple primary oral squamous cell carcinoma. *Oral Oncology*. 2013 May Volume 49, Supplement 1, pages S101.
2. Faisal Zawawi, Keith Richardson, Rickul Varshney, Jonathan Young, Alex M. Mlynarek, **Michael P. Hier**, and Richard J. Payne, Postthyroidectomy Throat Pain and Swallowing: Do Proton Pump Inhibitors Make a Difference?, Volume 2013 (2013), Article ID 135978, 4 pages
3. Sabrina Daniela Silva, **Moulay A. Alaoui-Jamali**, **Michael Hier**, Fernando Augusto Soares, Edgard Graner, Luiz Paulo Kowalski, Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread, *Clinical & Experimental Metastasis*, December 2013
4. Faisal Zawawi, Alex M Mlynarek, Arielle Cantor, Rickul Varshney, **Martin J Black**, **Michael P Hier**, Louise Rochon and Richard J Payne, Intraoperative parathyroid hormone level in parathyroidectomy: which patients benefit from it? *Journal of Otolaryngology - Head & Neck Surgery* 2013, 42:56 Published: 19 December 2013

**Department of Oncology
2013 Publications**

5. Scheffler P, Forest VI, Leboeuf R, Florea AV, Tamilia M, Sands NB, **Hier MP**, Mlynarek AM, Payne RJ. Serum Thyroglobulin Improves the Sensitivity of the McGill Thyroid Nodule Score for Well-Differentiated Thyroid Cancer. *Thyroid*. 2013 Dec 16.
6. Rassouli A, Saliba J, Castano R, **Hier M**, **Zeitouni AG**. Systemic inflammatory markers as independent prognosticators of Head and Neck Squamous cell carcinoma. *Head Neck*. 2013 Dec 13.
7. Saliba J, Payne RJ, Varshney R, Sela E, Maniakas A, Rahme E, Mlynarek A, Caglar D, **Hier MP**, Tamilia M. Sentinel Lymph Node Biopsy Status Correlates with Postoperative Stimulated Thyroglobulin Levels in Low-Risk Papillary Thyroid Cancer Patients. *Endocr Pract*. 2013 Dec 10:1-22.
8. Maniakas A, Forest VI, Jozaghi Y, Saliba J, **Hier MP**, Mlynarek A, Tamilia M, Payne RJ. Tumor classification in Well-Differentiated Thyroid Carcinoma and Sentinel Lymph Node Biopsy Outcomes: a Direct Correlation. *Thyroid*. 2013 Nov 8.
9. **Henry M**, Habib LA, Morrison M, Yang JW, Li XJ, Lin S, Zeitouni A, Payne R, Macdonald C, Mlynarek A, Kost K, **Black M**, **Hier M**. Head and Neck cancer patients want us to support them psychologically in the posttreatment period: Survey results. *Palliat Support Care*. 2013 Oct 24:1-13.
10. da Silva SD, **Alaoui-Jamali MA**, Soares FA, Carraro DM, Brentani HP, **Hier M**, Rogatto SR, Kowalski LP. TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. *Cancer*. 2013 Oct 21.
11. Jozaghi Y, Richardson K, Anand S, Mlynarek A, **Hier MP**, Forest VI, Sela E, Tamilia M, Caglar D, Payne RJ. Frozen section analysis and sentinel lymph node biopsy in well differentiated thyroid cancer. *J Otolaryngology Head Neck Surg*. 2013 Sep 11;42:48.

Nathalie Johnson

1. Nielsen TH, **Johnson NA**, Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, **Assouline S**, **Miller WH**, **Mann KK**. Monitoring response and resistance to the novel arsenical darinaparsin in an AML patient. *Front Pharmacol*. 2013;4:9. Epub 2013 Feb 12
2. Palumbo MO, **Kavan P**, **Miller WH Jr**, **Panasci L**, **Assouline S**, **Johnson N**, **Cohen V**, **Patenaude F**, **Pollak M**, **Jagoe RT**, **Batist G**. Systemic cancer therapy: achievements and challenges that lie ahead. *Front Pharmacol*. 2013 May 7;4:57.
3. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff R, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim E, **Johnson NA**, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell

**Department of Oncology
2013 Publications**

lymphoma using whole genome sequencing. *Blood*. 2013 Aug 15;122(7):1256-65, Epub May 22.

4. Varga C, Holcroft C, Kezouh A, Bucatel S, **Johnson N**, Petrogiannas-Haliotis T, **Assouline S**. Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B cell lymphoma: a population based study. *Leuk Lymphoma*. 2013 Epub Jul 5.

Petr Kavan

1. **Bouganim N**, Mamo A, Wasserman DW, **Batist G**, Metrakos P, **Chaudhury P**, Hassanain M, **Kavan P**. Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. *Oncol*. 2013 Oct;20(5):247-51. doi: 10.3747/co.20.1370. PubMed PMID: 24155628; PubMed Central PMCID: PMC3805399.
2. Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, **Kavan P**, Shacham-Shmueli E, Buchbinder A, Goldberg. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. *RM.Cancer*. 2013 Dec 15;119(24):4223-30. doi: 10.1002/cncr.28358. Epub 2013 Sep 16. PMID: 24105075 [PubMed - in process] Select item 23743930
3. Diaz Z, Aguilar-Mahecha A, Paquet ER, **Basik M**, Orain M, Camlioglu E, Constantin A, Benlimame N, Bachvarov D, Jannot G, Simard MJ, Chabot B, Gologan A, Klinck R, Gagnon-Kugler T, Lespérance B, Samson B, **Kavan P**, **Alcindor T**, **Dalfen R**, Lan C, Chabot C, Buchanan M, Przybytkowski E, Qureshi S, Rousseau C, **Spatz A**, Têtu B, **Batist G**. Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. *Mod Pathol*. 2013 Nov;26(11):1413-24. doi: 10.1038/modpathol.2013.81. Epub 2013 Jun 7. PMID: 23743930 [PubMed - in process]
4. Palumbo MO, **Kavan P**, **Miller WH Jr**, **Panasci L**, **Assouline S**, **Johnson N**, **Cohen V**, **Patenaude F**, **Pollak M**, **Jagoe RT**, **Batist G**. Systemic cancer therapy: achievements and challenges that lie ahead. *Front Pharmacol*. 2013 May 7;4:57. doi: 10.3389/fphar.2013.00057. eCollection 2013. PMID: 23675348 [PubMed]. Select item 23419575
5. Mamo A, Nogueira MC, **Batist G**, Palumbo M, **Panasci L**, **Ferrario C**, **Chaudhury P**, Metrakos P, **Kavan P**. A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. *Curr Oncol*. 2013 Apr;20(2):e107-12. doi: 10.3747/co.20.1271. PubMed PMID: 23559877; PubMed Central PMCID: PMC3615861.
6. Sahebjam S, Garoufalis E, Guiot MC, **Muanza T**, Del Maestro R, **Petrecce K**, Sharma R, **Kavan P**. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. *Can J Neurol Sci*. 2013 Mar;40(2):241-6

Neil Kopek

1. **Faria S**, **Kopek N**, **Hijal T**, **Liberman S**, Charlebois P, Stein B, **Meterissian S**, **Meguerditchian A**, Fawaz Z, Artho G. Phase II trial of short-course radiotherapy followed by

**Department of Oncology
2013 Publications**

delayed surgery for locoregionally advanced rectal cancer. *Colorectal Dis.* 2014 Feb;16(2):O66-70.

2. **N. Kopek.** Cancer of the Pancreas in: Radiation Therapy in Oncology. Eds. J. Salvajoi, L. Souhami, S. Faria. Editora Atheneu. 2013.
3. **N. Kopek.** Cancer of the liver and biliary tree in: Radiation Therapy in Oncology. Eds. J. Salvajoi, L. Souhami, S. Faria. Editora Atheneu. 2013.
4. Gino Boily, Édith Filion, **Neil Kopek**, George Rakovich, Isabelle Roy, Benoit Samson, Lise Tremblay. Utilisation de la radiothérapie stéréotaxique d'ablation (SABR) pour le traitement du cancer du poumon non à petites cellules. Comité de l'évolution des pratiques en oncologie (CEPO). Bibliothèque et Archives nationales du Québec, 2013; Bibliothèque et Archives Canada, 2013. www.msss.gouv.qc.ca/cancer.

Antonis Koromilas

1. **Koromilas AE**, Sexl, V 2013 "The tumor suppressor function of Stat1 in breast cancer." *JAK-STAT* 2:2, e23353
2. Krokowski D, Han J, Saikia M, Majumder M, Yuan CL, Guan BJ, Bevilacqua E, Bussolati O, Broer S, Arvan P, Tchorzewski M, Snider MD, Puchowicz M, Croniger CM, Kimball SR, Pan T, **Koromilas AE**, Kaufman RJ, Hatzoglou M. 2013. "A self-defeating anabolic program leads to beta-cell apoptosis in endoplasmic reticulum stress-induced diabetes via regulation of amino acid flux." *Journal Biological Chemistry.* **288**:17202-17213.
3. **Koromilas AE**, Mounir Z. 2013 "Control of oncogenesis by eIF2alpha phosphorylation: Implications in PTEN and PI3K-Akt signaling and tumor treatment." *Future Oncology* **9**:1005-15.
4. Rajesh K, Papadakis AI, Kazimierczak U, Peidis P, Wang S, Ferbeyre G, Kaufman RJ, **Koromilas AE** 2013 "eIF2 α phosphorylation bypasses senescence caused by oxidative stress and pro-oxidant antitumor therapies." *Aging (Albany NY)* **5**:884-901.

Carmen Loiselle

1. Wurz, AJ., & **Loiselle, CG.** (2013). Psychosocial care: Video-based CBT for insomnia. Report from the Canadian Association of Psychosocial Oncology Conference. *Oncology Exchange*, 12(2), 33-34.
2. Macrae, L., De Souza, A.N., Wong, N. & **Loiselle, C.G.** (2013). Experience of BRCA 1/2 mutation-negative young women from families with hereditary breast and ovarian cancer: A qualitative study. *Hereditary Cancer in Clinical Practice*, 11(1), 14. doi: 10.1186/1897-4287-11-14 PMID: 24131499
3. **Loiselle, C.G.**, Peters, O., Haase, K.R., Girouard, L., **Koerner, A.**, Wiljer, D., & Fitch, M. (2013). Virtual navigation in colorectal cancer and melanoma: An exploration of patients' views. *Supportive Care in Cancer*, 21(8), 2289-2296. PMID: 23519565

**Department of Oncology
2013 Publications**

4. Pluye, P., Grad, R.M., Repchinsky, C., Jovaisas, B., Johnson-Lafleur, J., Carrier, M.E., Granikov, V., Farrell, B., Rodriguez, C., Bartlett, G., **Loiselle, C.** & Légaré, F. (2013). Four levels of outcomes of information-seeking: A mixed methods study in primary health care. *Journal of the American Society for Information Science and Technology (JASIST)*, 64(1), 108-125.

Koren Mann

1. ADR Kelly, M Lemaire, YK Young, JH Eustache, C Guilbert, M Flores Molina, and **KK Mann**. *In vivo* tungsten exposure alters B cell development and increases DNA damage in murine bone marrow. *Tox Sci* 131(2):434-46, 2013.
2. TH Nielsen, N Johnson, N Garnier, S Kwan, E Cocolakis, J Hébert, RA Morgan, É Paquet, KP Callahan, CT Jordan, **S Assouline, WH Miller Jr.** and **KK Mann**. Monitoring response and resistance to the novel arsenical darinaparsin in an AML patient. *Frontiers in Pharmacology of Anti-Cancer Drugs* 4:9; 2013.
3. N Garnier, LA Petrucci, M Flores Molina, M Kourelis, S Kwan, Z Diaz, HM Schipper, A Gupta, S Del Rincon, **KK Mann**, and **WH Miller Jr.** The novel arsenical darinaparsin circumvents BRG1-dependant, HO-1 mediated cytoprotection in leukemia cells. *Leukemia* Nov;27(11):2220-8, 2013.
4. F Hariri, M Arguello, L Volpon, B Culjkovic-Kraljacic, TH Nielsen, S Oliere, **KK Mann**, J Hiscott, and KLB Borden. The eukaryotic translation initiation factor eIF4E is a direct NF- κ B target gene. *Leukemia* Oct;27(10):2047-55, 2013.
5. M Li, M Oneeb, R Mian, T Barhoumi, A Rehman, **K Mann**, P Paradis, and E Schiffrin. Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice. *ATVB* Oct;33(10):2306-15, 2013.
6. C Guilbert, MG Annis, Z Dong, **PM Siegel, WH Miller Jr, KK Mann**. Arsenic Trioxide Overcomes Rapamycin-Induced Feedback Activation of AKT and ERK Signaling to Enhance the Anti-Tumor Effects in Breast Cancer. *PLoS One*. Dec 31;8(12):e85995, 2013.

Luke McCaffrey

1. **McCaffrey, L.**, Macara, I.G. (2013) Cell Polarity in Morphogenesis and Metastasis. *Phil Trans R Soc B* 368(1629):20130012.
2. Rejon, C. and **McCaffrey, L1**. Cell Polarity in Mammary Gland Morphogenesis and Breast Cancer. Book chapter in "Cell Polarity". Springer Press. Ed. Klaus Ebnet.

Wilson Miller

1. Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilias G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, **Miller WH Jr**, Tassell V, Huang X, Paolini J, A Kern KA, Gilles Romieu G. Phase III Trial of Sunitinib in Combination with Capecitabine versus Capecitabine Monotherapy for the Treatment of Patients with Pretreated Metastatic

**Department of Oncology
2013 Publications**

Breast Cancer. JCO. 31(23):2870-78, 2013.

2. Garnier N, Petruccelli L A, Molina M F, Kourelis M, S Kwan S, Diaz A, Schipper H M, Gupta A, Del Rincon S, **Mann K K**, and **Miller WH Jr**. The novel arsenical darinaparsin circumvents BRG1-dependant, HO-1-mediated cytoprotection in leukemic cells. Leukemia. doi: 10.1038/leu.2013.54. [Epub 2013 Feb 21]
3. Petruccelli L A, Pettersson F, del Rincón S V, Guilbert C, Licht J D, **Miller WH Jr**. Expression of leukemia associated fusion proteins increases sensitivity to histone deacetylase inhibitor induced DNA damage and apoptosis. Molecular Cancer Therapeutics. Molecular Cancer Therapeutics. DOI: 10.1158/1535-7163.MCT-12-1039 [Epub 2013 March 27].
4. Nielsen TH, **Johnson N**, Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, **Assouline S**, **Miller WH Jr**, and **Mann KK**. Monitoring response and resistance 1 to the novel arsenical 2 darinaparsin in an AML patient. Frontiers in Pharmacology of Anti-Cancer Drugs. 4:9, 2013.
5. Jimeno A, Weiss G, **Miller WH Jr**, Gettinger S, Eigl B, Chang A, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis K, Tibes R, Sharfman W, Ross R, and Rudin C. Phase 1 Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. Clinical Cancer Research. 2013 May 15;19(10):2766-2774. [Epub 2013 Apr 10.]
6. Palumbo MO, **Kavan P**, **Miller WH Jr**, **Panasci L**, **Assouline S**, **Johnson N**, Cohen V, **Patenaude F**, **Pollak M**, **Jagoe RT** and **Batist G**. Systemic cancer therapy: achievements and challenges that lie ahead.Frontiers in Pharmacology of Anti-Cancer Drugs; 4:57, 2013.
7. **Aloyz R**, Martinez-Marignac V, Shawi M, Pinedo-Carpio E, **Panasci L**, **Miller WH Jr** and Pettersson F. Pharmacological targeting of eIF4E in primary CLL lymphocytes. Blood Cancer Journal (2013) 3, e146; doi:10.1038/bcj.2013.43. Published online 13 September 2013.
8. Soye K J, Trottier C, Di Lenardo T Z, Restori K H, Reichman L, **Miller WH Jr** and Ward B J. In vitro inhibition of mumps virus by retinoids. Virology Journal. 10(1):337. doi: 10.1186/1743-422X-10-337, 2013.
9. Guilbert C, Annis MG, Dong Z, Siegel PM, **Miller WH Jr**, **Mann KK**. Arsenic Trioxide Overcomes Rapamycin-Induced Feedback Activation of AKT and ERK Signaling to Enhance the Anti-Tumor Effects in Breast Cancer. Plos One. 8:12 | e85995, 2013.

Thierry Muanza

1. Krauze AV, Won M, Graves C, Corn BW, **Muanza TM**, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA. Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomark Res. 2013 Oct 31;1(1):29. doi: 10.1186/2050-7771-1-29.

**Department of Oncology
2013 Publications**

2. Sahebjam S, Garoufalidis E, Guiot MC, **Muanza T**, Del Maestro R, **Petrecca K**, Sharma R, **Kavan P**. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. *Can J Neurol Sci.* 2013 Mar;40(2):241-6.

Alain Nepveu

1. Vadnais, C., A. A. Awan, L. Leduy, G. Bérubé, and **Alain Nepveu**. Long-Range Transcriptional Regulation by the p110 CUX1 Homeodomain Protein on the ENCODE Array. *BMC Genomics.* <http://www.biomedcentral.com/1471-2164/14/258>. 2013.

Lawrence Panasci

1. Martinez-Marignac V, Shawi M, Pinedo-Carpio E, Wang X, **Panasci L**, **Miller W**, Pettersson F, **Aloyz R**. Pharmacological targeting of e1F4E in 12rimarx CLL Lymphocytes. *Blood Cancer J.* 2013 Sep 13;3:e 146. doi: 10.1038/bcj.2013.43
2. Palumbo MO, **Kavan P**, **Miller WH Jr**, **Panasci L**, **Assouline S**, **Johnson N**, **Cohen V**, **Patenaude F**, **Pollak M**, **Jagoe RT**, **Batist G**. Systemic cancer therapy: achievements and challenges that lie ahead. *Front Pharmacol.* 2013 May 7;4:57. doi: 10.3389/fphar.2013.00057
3. Mamo A, Nogueira MC, **Batist G**, Palumbo M, **Panasci L**, **Ferrario C**, **Chaudhury P**, **Metrakos P**, **Kavan P**. A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. *Curr Oncol.* 2013
4. Davidson D, Amrein L, **Panasci L**, **Aloyz R**. Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. *Front Pharmacol.* 2013 Jan 31 ;4:5. doi: 10.3389/fphar.2013.00005
5. Amrein L, Shawi M, Grenier J, **Aloyz R**, **Panasci L**. The Phosphatidylinositol-3 kinase I inhibitor BKM 120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. *Int J Cancer.* 2013 Jul;133(1):247-52
6. Davidson D, Wang Y, **Aloyz R**, **Panasci L**. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. *Invest New Drugs.* 2013 Apr;31 (2):461-8. doi: 10.1007/s10637-012-9886-7

Morag Park

1. Wallace JA, Li F, Balakrishnan S, Cantemir-Stone CZ, Pecot T, Martin C, Kladney RD, Sharma SM, Trimboli AJ, Fernandez SA, Yu L, Rosol TJ, Stromberg PC, Lesurf R, Hallett M, **Park M**, Leone G, Ostrowski MC. Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer. *PLoS One.* 2013 Aug 16;8(8):e71533. doi: 10.1371/journal.pone.0071533. eCollection 2013.
2. Ahn R, Sabourin V, Ha JR, Cory S, Maric G, Im YK, Hardy WR, Zhao H, **Park M**, Hallett M, Siegel PM, Pawson T, **Ursini-Siegel J**. The ShcA PTB domain functions as a biological

**Department of Oncology
2013 Publications**

sensor of phosphotyrosine signaling during breast cancer progression. *Cancer Res.* 2013 Jul 15;73(14):4521-32. doi: 10.1158/0008-5472.CAN-12-4178. Epub 2013 May 21.

3. Laurin M, Huber J, Pelletier A, Houalla T, **Park M**, Fukui Y, Haibe-Kains B, Muller WJ, Côté JF. Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis. *Proc Natl Acad Sci U S A.* 2013 Apr 30;110(18):7434-9. doi: 10.1073/pnas.1213050110. Epub 2013 Apr 16.
4. Ursini-Siegel J, **Park M**. It takes two to tango in the microenvironment! *Breast Cancer Res.* 2013 Mar 12;15(2):102. [Epub ahead of print] PMID: 23510134 [PubMed - as supplied by publisher] Free PMC Article

William Parker

1. R Al-Wassia, H Bahig, E Poon, **W Parker**, **C Freeman**, Daily setup uncertainty analysis for craniospinal irradiation using helical tomotherapy, *Practical Radiation Oncology* 3 (4), 349-355
2. SD Davis, **W Parker**, **MDC Evans** Using mean dose rate to compare relative dosimetric efficiency with respect to source type and source change schedules for HDR brachytherapy, *Journal of Applied Clinical Medical Physics* 14 (6)
3. Y Cui, JM Galvin, **W Parker**, S Breen, FF Yin, J Cai, LS Papiez, XA Li, ...Implementation of remote 3-dimensional image guided radiation therapy quality assurance for Radiation Therapy Oncology Group clinical trials, *International Journal of Radiation Oncology* Biology* Physics* 85 (1), 271-277

Horacio Patrocinio

1. **W. Parker**, **H. Patrocinio**, “Radioterapia conformacional: simulação e planejamento do tratamento.” Book chapter in “Radioterapia em Oncologia, 2 ed.”, J. Salvajoli, L. Souhami, S. Faria, eds. Editora Atheneu, p.141-156, 2013 Brazil.
2. **H. Patrocinio**, **W. Parker**, **E. Soisson**, “Radioterapia de intensidade modulada (IMRT).” Book chapter in “Radioterapia em Oncologia, 2 ed.”, J. Salvajoli, L. Souhami, S. Faria, eds. Editora Atheneu, p. 193-210, 2013 Brazil.
3. **E. Soisson**, **W. Parker**, **H. Patrocinio**, “Radioterapia com orientação por imagem (IGRT)”. Book chapter in “Radioterapia em Oncologia, 2 ed.”, J. Salvajoli, L. Souhami, S. Faria, eds. Editora Atheneu, p211-224, 2013 Brazil.

Michael Pollak

1. Liao LM, Schwartz K, **Pollak M**, Graubard BI, Li Z, Ruterbusch J, Rothman N, Davis F, Wacholder S, Colt J, Chow WH, Purdue MP. Serum leptin and adiponectin levels and risk of renal cell carcinoma. *Obesity* 21: 1478-85, 2013.
2. Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, Lacroix A, Tice JA, Chia VM, Falk R, Pfeiffer R, **Pollak MN**, Veenstra TD, Xu X, Lacey JV. Obesity-related

**Department of Oncology
2013 Publications**

- hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. *Endocr Relat Cancer* 20: 151-60, 2013.
3. Bao Y, Giovannucci EL, Kraft P, Stamfer MJ, Ogino S, Ma J, Buring JE, Sesson HD, Lee IM, Gaziano JM, Rifai N, **Pollak MN**, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. *J Natl Cancer Inst* 105: 95-103, 2013.
 4. Smiechowski BB, Azoulay L, Yin H, **Pollak MN**, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. *Diabetes Care* 36: 124-9, 2013.
 5. Liao LM, Weinstein SJ, **Pollak M**, Li Z, Virtamo J, Albanes D, Chow WH, Purdue MP. Pre-diagnostic circulating adipokine concentrations and risk of renal cell carcinoma. *Carcinogenesis* 34: 109-12, 2013.
 6. Lubik AA, Gunter JH, Hollier BG, Fazli L, Ettinger S, Stylianou N, Adomat H, Hendy SC, Gleave M, **Pollak MN**, Herington A, Nelson CC. IGF2 increases de novo steroidogenesis in prostate cancer cells. *Endocr Relat Cancer* 20: 173-86, 2013.
 7. Neuhaus ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HI, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, **Pollak M**. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Cancer Prev Res (Phila)* 6: 91-9, 2013.
 8. Song Y, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, **Pollak M**, Liu S, Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. *J Nutr* 143: 189-96, 2013.
 9. Hofmann J, Liao L, **Pollak M**, Wang Ye, Pfeiffer R, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue M. A prospective study of circulating adipokine levels and risk of multiple myeloma. *Cancer Epidemiol Biomarkers Prev* 22: 472, 2013.
 10. Bao Y, Giovannucci E, Kraft P, Qian ZR, Wu C, Ogino S, Gaziano JM, Stampfer MJ, Ma J, Buring JE, Sesso H, Lee IM, Rifai N, **Pollak MN**, Jiao L, Lessin LS, Cochrane BB, Manson JE, Fuchs CS, Wolpin BM. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of 5 US cohorts. *Cancer J Natl Cancer Inst* 105: 95-103, 2013.
 11. Moiseeva O, Deschenes-Simard X, St-Germian E, Igelmann S, Huot G, Cadar AE, Bourdeau V, **Pollak MN**, Ferbeyre G. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF- κ B activation. *Aging Cell* 12: 489-98, 2013.
 12. **Pollak M**. Targeting oxidative phosphorylation: why, when, and how. *Cancer Cell* 23: 263-4, 2013.

**Department of Oncology
2013 Publications**

13. *Assayag J, Yin H, Benayoun S, **Pollak MN**, Suissa S, **Azoulay L**. Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer. *Cancer Causes Control* 24: 839-45, 2013.
14. Vandersluis AD, Venier NA, Colquhoun AJ, Sugar L, **Pollak M**, Kiss A, Fleshner NE, Klotz LH, Venkateswaran V. Exercise does not counteract the effects of a "westernized" diet on prostate cancer xenografts. *Prostate* 73: 1223-32, 2013.
15. Palumbo MO, **Kavan P**, **Miller WH Jr**, **Panasci L**, **Assouline S**, **Johnson N**, **Cohen V**, **Patenaude F**, **Pollak M**, **Jagoe RT**, **Batist G**. Systemic cancer therapy: achievements and challenges that lie ahead. *Front Pharmacol* 4: 57, 2013
16. Moiseeva O, Deschênes-Simard X, **Pollak M**, Ferbeyre G. Metformin, aging and cancer. *Aging* 5: 330-1, 2013.
17. Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente LP, Blenis J, **Pollak MN**, Olumi AF, Vander Heiden M, Stephanopoulos G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. *Cancer Res* 73: 4429-4438, 2013.
18. Takahara K, Ibuki N, Ghaffari M, Tearle H, Ong CJ, Azuma H, Gleave ME, **Pollak M**, Cox ME. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice. *Prostate Cancer Prostatic Dis* 16: 239-47, 2013.
19. Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Prakash Somasekharan S, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, Barokas A, Kwok B, Bowden M, Smith S, Wu X, Korshunov A, Hielscher T, Northcott PA, Galpin JD, Ahern CA, Wang Y, McCabe MG, Collins VP, Jones RG, **Pollak M**, Delattre O, Gleave ME, Jan E, Pfister SM, Proud CG, Derry WB, Taylor MD, Sorensen PH. The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. *Cell* 153: 1064-79, 2013.
20. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, **Pollak MN**, Manson JE, Giovannucci EL, Fuchs CS. Hyperglycemia, Insulin Resistance, Impaired Pancreatic β -Cell Function, and Risk of Pancreatic Cancer. *J Natl Cancer Inst* 105: 1027-35, 2013.
21. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin MJ, Schwab M, **Pollak M**, Zhang Y, Yu Y, Becker KG, Bohr VA, Ingram DK, Sinclair DA, Wolf NS, Spindler SR, Bernier M, de Cabo R. Metformin improves healthspan and lifespan in mice. *Nat Commun* 4, 2013.

**Department of Oncology
2013 Publications**

22. Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, **Pollak M**, Charbonnel B, Riddle M, Mignot L, Boivin JF, Khachatryan A, Rossignol M, Bénichou J, Alperovitch A, Abenheim L. Risk of breast cancer by individual insulin use - an international multicenter study. *Diabetes Care* 37: 134-43, 2013.
23. Smiechowski B, **Azoulay L**, Yin H, **Pollak MN**, Suissa S. The use of metformin and colorectal cancer incidence in patients with type 2 diabetes mellitus. *Cancer Epidemiol Biomarkers Prev* 22: 1877-1883, 2013.
24. **Pollak M**. Potential applications for biguanides in oncology. *J Clin Invest* 123: 3693-700, 2013.
25. Ahern TP, Hankinson SE, Willett WC, **Pollak MN**, Eliassen AH, Tamimi RM. Plasma C-Peptide, Mammographic Breast Density, and Risk of Invasive Breast Cancer. *Cancer Epidemiol Biomarkers Prev* 22: 1786-1796, 2013.
26. Li R, Montpetit A, Rousseau M, Wu SY, **Greenwood CM**, Spector TD, **Pollak M**, Polychronakos C, Richard JB. Somatic point mutations occurring early in development: a monozygotic twin study. *J Med Genet* 51: 28-34, 2013.
27. *Hvid H, Blouin MJ, Birman E, Damgaard J, Poulsen F, Fels JJ, Fledelius C, Hansen BF, **Pollak M**. Treatment with Insulin Analog X10 and IGF-1 Increases Growth of Colon Cancer Allografts. *PLoS One*. 2013 Nov 18.
28. Van Dang C, **Pollak M**. Why Cancer & Metabolism? Why now? *Cancer Metab* 1: 1, 2013.
29. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, **Pollak M**, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA. Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. *J Natl Cancer Inst* 105: 1881-90, 2013.
30. Muhlbradt E, Ma J, Severi G, Ortner E, Hayes V, Hoang HN, Stampfer M, Giles G, **Pollak M**, Gelmann EP. Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. *Genes Cancer* 4: 535-45, 2013.
31. **Pollak M**. Metformin's Potential in Oncology. *Clin Adv Hematol Oncol* 11: 594-5, 2013.

Stéphane Richard

1. *Binda O., G. LeRoy, M. Jangal, A. N. Markovits, A. Sevilla, I. Lemischka, B. A. Garcia, N. Gévry, and **S. Richard**. Regulation of methylated H2AZ by SETD6 estrogen receptor-regulated promoters. *Epigenetics*. 2013 8:177-83
2. *Wang Y, G. Vogel, Z. Yu, and **S. Richard**. 2013. The QKI-5 and QKI-6 RNA binding proteins regulate the expression of miR-7 in glial cells. *Mol Cell Biol* 33:1233-43.

**Department of Oncology
2013 Publications**

3. Dhar S, Vemulapalli V, Patananan AN, Huang GL, Di Lorenzo A, **Richard S**, Comb MJ, Guo A, Clarke SG, Bedford MT. 2013. Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs. *Sci Rep*. 2013 Feb 19;3:1311
4. Fu K., X. Sun, W. Zheng, E. M. Wier, A. Hodgson, D.Q. Tran, **S. Richard** and F. Wan. 2013. Sam68 modulates the promoter specificity of NF- κ B and mediates expression of CD25 in activated T cells. *Nat Comm*. 4:1909
5. Thandapani, P., T. R. O'Connor, T. Bailey and **S. Richard** 2013. Defining the RGG-RG motif. *Molecular Cell* 50:613-623

Siham Sabri

1. David Lesniak, **Siham Sabri**, Yaoxian Xu, Kathryn Graham, Pravin Bhatnagar, Suresh Mavanur and **Bassam Abdulkarim**. Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer. *Plos One* 2013 Aug 26;8(8):e71987.

Jan Seuntjens

1. Chung E, Davis S, **Seuntjens J**. Experimental analysis of general ion recombination in a liquid-filled ionization chamber in high-energy photon beams. *Med Phys*. 2013 Jun;40(6):062104. doi: 10.1118/1.4805109.
2. Tran SD, Liu Y, Xia D, Maria OM, Khalili S, Wang RW, Quan VH, Hu S, **Seuntjens J**. Paracrine effects of bone marrow soup restore organ function, regeneration, and repair in salivary glands damaged by irradiation. *PLoS One*. 2013 Apr 24;8(4):e61632. doi: 10.1371/journal.pone.0061632. Print 2013.
3. Papaconstadopoulos P, **Seuntjens J**. A source model for modulated electron radiation therapy using dynamic jaw movements. *Med Phys*. 2013 May;40(5):051707. doi: 10.1118/1.4800492.
4. Conneely E, Alexander A, Stroian G, **Seuntjens J**, Foley MJ. An investigation into the use of MMCTP to tune accelerator source parameters and testing its clinical application. *J Appl Clin Med Phys*. 2013 Mar 4;14(2):3692. doi: 10.1120/jacmp.v14i2.3692.
5. Renaud J, Marchington D, **Seuntjens J**, Sarfehnia A. Development of a graphite probe calorimeter for absolute clinical dosimetry. *Med Phys*. 2013 Feb;40(2):020701. doi: 10.1118/1.4773870.

Luis Souhami

1. Cairncross G, Wang M, Shaw, E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, **Souhami L**, Laperriere N, Curran W, Mehta M. A Phase III trial of chemoradiotherapy for anaplastic oligodendrogliomas: long-term results of RTOG 9402. *J Clin Oncol* 31:337-343, 2013.

**Department of Oncology
2013 Publications**

2. **Petrecce K**, Guiot M-C, **Panet-Raymond V**, **Souhami L**. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margins in patients with glioblastoma. *J Neurooncol* 111:19-23, 2013.
3. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, **Souhami L**, Buyyounouski MK, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry G, Suh JH, Mehta MP. A Phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. *Int J Radiat Oncol Biol Phys* 85 1312-1318, 2013.
4. Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D'Souza D, **Souhami L**, Small W Jr, Gaur R, Jhingran A. Hematologic Toxicity in RTOG 0418: A Phase 2 study of postoperative IMRT for gynecologic cancer. *Int J Radiat Oncol Biol Phys* 86: 83-90, 2013.
5. Patel N, **Faria S**, **Cury F**, **David M**, **Duclos M**, **Shenouda G**, Ruo R, **Souhami L**. Hypofractionated Radiation Therapy (66 Gy in 22 Fractions at 3 Gy per Fraction) for Favorable-Risk Prostate Cancer: Long-term Outcomes. *Int J Radiat Oncol Biol Phys*. 86:534-9, 2013.
6. **Cury F**, **Souhami L**. Principios de Radioterapia. In *Tratado de Oncologia*. Hoff P (ed). 2013. Atheneu Sao Paulo, SP, pp 557-574, 2013.
7. Bernad D (*resident in our program*), **Souhami L**. Tumor do canal medular. In *Radioterapia em Oncologia* (2nd edition). Salvajoli JV, **Souhami L**, **Faria SL** (eds). Atheneu, Sao Paulo, Brazil, pp 475-483.
8. Rene N, **Souhami L**. Bexiga. In *Radioterapia em Oncologia* (2nd edition). Salvajoli JV, **Souhami L**, **Faria SL** (eds). Atheneu, Sao Paulo, Brazil, pp 851-874, 2013.
9. Da Silva JLF, Marta GN, Hanna SA, Faria SL, **Souhami L**. In *Radioterapia em Oncologia* (2nd edition). Salvajoli JV, **Souhami L**, **Faria SL** (eds). Atheneu, Sao Paulo, Brazil, pp 875-912.
10. Carvalho HA, Stuart SR, **Souhami L**. In *Radioterapia em Oncologia* (2nd edition). Salvajoli JV, **Souhami L**, **Faria SL** (eds). Atheneu, Sao Paulo, Brazil, pp 939-974, 2013.
11. **Souhami L**. Cancer do endometrio. In *Radioterapia em Oncologia* (2nd edition). Salvajoli JV, **Souhami L**, **Faria SL** (eds). Atheneu, Sao Paulo, Brazil, pp 975-995, 2013.

Ivan Topisirovic

1. Gandin V, Gutierrez GJ, Brill LM, Varsano T, Feng Y, Aza-Blanc P, Au Q, McLaughlan S, Ferreira TA, Alain T, Sonenberg N, **Topisirovic I***, Ronai ZA*. (2013) Degradation of newly synthesized polypeptides by ribosome-associated RACK1/c-Jun N-terminal kinase/eukaryotic elongation factor 1A2 complex. *Mol Cell Biol*. 33(13):2510-26 (*co-corresponding author)

**Department of Oncology
2013 Publications**

2. Bjur E, Larsson O, Yurchenko E, Zheng L, Gandin V, **Topisirovic I**, Li S, Wagner CR, Sonenberg N, Piccirillo CA. (2013) Distinct translational control in CD4+ T cell subsets. *PLoS Genet.* 9(5):e1003494.
3. Svitkin YV, Yanagiya A, Karetnikov A, Alain T, Fabian MR, Perreault S, **Topisirovic I**, Sonenberg N. (2013) Control of Translation and miRNA-Dependent Deadenylation by a Novel Poly(A) Binding Protein, hnRNP-Q *PLoS Biology* 11(5):e1001564. doi: 10.1371.
4. Gandin V*, Daniela Senft*, **Topisirovic I****, Ze'ev A. Ronai** RACK1 Function in Cell Motility and Protein Synthesis (2013) *Genes & Cancer* April 21, doi: 10.1177/1947601913486348 (*equally contributing first authors; **co-corresponding authors).
5. Morita M, Gravel SP, Chénard V, Sikström K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, McLaughlan S, Nouet Y, Pause A, Pollak M, Gottlieb E, Larsson O, St-Pierre J*, **Topisirovic I***, Sonenberg N * (2013) mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. *Cell Metabolism* 18(5):698-711 (*co-corresponding authors).
6. Gandin V, **Topisirovic I**. (2013) Cell biology. Trans-HSF1 express. *Science.* 19;341(6143):242-3.

Anna Towers

1. *Anne L. Newman, Leonard Rosenthal, **Anna Towers**, Pamela Hodgson, Casi Shay, Dorit Tidhar, **Antonio Vigano**, Robert D. Kilgour. Determining the precision of dual energy x-ray absorptiometry and multi-frequency bioelectric impedance spectroscopy in the assessment of breast cancer-related lymphedema. *Lymphatic Research and Biology*, 2013, 11(2):104-109, DOI: 10.1089/lrb.2012.0020

Josie Ursini-Siegel

1. Ryuhjin Ahn, Valerie Sabourin, Sean Cory, Gordana Maric, Young K. Im, W. Rod Hardy, Hong Zhao, **Morag Park**, Michael Hallett, **Peter M. Siegel**, Tony Pawson and **Josie Ursini-Siegel**. 2013 The ShcA PTB Domain Functions as a Biological Sensor of Phospho-tyrosine Signaling During Breast Cancer Progression. *Cancer Research*, 73: 4521-32.
2. **Josie Ursini-Siegel** and **Morag Park**. 2013. It takes two to tango in the microenvironment! *Breast Cancer Research.* 15:102.
3. Dery MA*, Jodoin J*, **Ursini-Siegel J**, Aleynikova O, Ferrario C, Hassan S, **Basik M**, Leblanc AC. 2013. Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer. *Breast Cancer Research.* 15:R22 *co-first authors
4. Ngan E, Northey JJ, Brown CM, **Ursini-Siegel J**, **Siegel PM**. 2013. A complex containing LPP and α -actinin mediates TGF β -induced migration and invasion of ErbB2-expressing breast cancer cells. *J. Cell Science.* doi:10.1242/jcs.118315
5. **Josie Ursini-Siegel**. 2013. Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune based therapies? *Frontiers in Pharmacology.* 3: 23

**Department of Oncology
2013 Publications**

Marie Vanhuyse

1. Madani A, Spicer J, **Alcindor T, David M, Vanhuyse M, Asselah J, Mulder D, Ferri L.** J Clinical Significance of Incidental Pulmonary Nodules in Esophageal Cancer Patients. *Gastrointest Surg.* 2013 Sep 4.

Antonio Vigano

1. Kilgour RD, **Vigano A**, Trutschnigg B, Lucar E, **Borod M**, Morais JA. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. *J Support Care Cancer* 2013; 21: 3261-3270. doi:10.1007/s00520-013-1894-4
2. Trutschnigg B*, Kilgour RD, Morais JA, Lucar E, Hornby L, Molla H, **Vigano A.** Metabolic, nutritional and inflammatory characteristics in elderly women with advanced gastrointestinal cancer. *J Geriatr Oncol.* 2013 Apr;4(2):183-9. doi: 10.1016/j.jgo.2012.09.002. Epub 2012 Sep 29
3. Newman AL*, Rosenthal L, **Towers A**, Hodgson P, Shay CA, Tidhar D, **Vigano A**, Kilgour RD. Determining the precision of dual energy x-ray absorptiometry and bioelectric impedance spectroscopy in the assessment of breast cancer-related lymphedema. *Lymphat Res Biol.* 2013 Jun;11(2):104-9.

Té Vuong

1. Webster MJ, **Devic S, Vuong T**, Han D, Park J Custin, Scanderbeg D, Lawson J, Einck J, Jia X, Pawlicki, Bongyong Song T, Watkins WT, Song WY. Dynamic Modulated Brachytherapy (DMBT) for rectal cancer. *Medical Physics*, Volume 40, Issue 1, Pages 011718-1- 011718-2, January 2013
2. Thariat J, Hannoun-Levi J-M, Sun Myint A, **Vuong T**, Gerard J-P. Past, present, and future of radiotherapy for the benefit of patients. *Nature Reviews Clinical Oncology*, Volume 10, No 1, Pages 52-60, January 2013
3. Hesselager C, **Vuong T**, Pahlman L, **Liberman S**, Letellier F, Folkesson J. Short term outcomes after neoadjuvant high dose rate endorectal brachytherapy versus short course external beam radiotherapy in resectable rectal cancer. *Colorectal Disease*, Volume 15, Issue 6, pages 662–666, June 2013.
4. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. **Vuong T** (co-author) *British Journal of Surgery*, Volume 100, Issue 8, pages 1009-E33, July 2013
5. Webster M, **Devic S, Vuong T**, Scanderbeg D, Han D, Song W. HDR Brachytherapy of Rectal Cancer Using a Novel Grooved-Shielding Applicator Design, *Medical Physics*, Volume 40, No. 9, September 2013

**Department of Oncology
2013 Publications**

6. N. Ouhoummane, M. Steben, F. Coutlée, **Te Vuong**, P. Forest, C. Rodier, R. Louchini. E. Duarte, P. Brassard. Squamous anal cancer: Patient characteristics and HPV type distribution *Cancer Epidemiology* (2013), <http://dx.doi.org/10.1016/j.canep.2013.09.015>

Jian Hui Wu

1. Krikor Bijian, Caroline Lougheed, Su Jie, Bin Xu, Henry Yu, **Jian Hui Wu**, Karina Riccio, and **Moulay Alaoui-Jamali**. Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine. *British Journal of Cancer*, 2013, **109**, 2810–2818.
2. Yebdri FB, Vangrevenynghe J, Tang VA, Goulet ML, **Wu J**, Stojdl DF, Hiscott J, Lin R. Triptolide Mediated-Inhibition of Interferon Signaling Enhances Vesicular Stomatitis Virus based Oncolysis. *Molecular Therapy*, 2013, 21(11):2043-53.
3. **Wu, J.H. & Batist, G.** Glutathione and glutathione analogues: therapeutic potentials. *BBA – General Subjects*, 2013, 1830:3350-3353 (invited review).
4. #Xiaohong Tian and ***Jian Hui Wu**. Tanshinone derivatives: A patent review (January 2006-September 2012). *Expert Opinion on Therapeutic Patents*, 2013, 23:19-29 (Invited review).

Anthony Zeitouni

1. Al Hinai Q, **Zeitouni A**, Sirhan D, Sinclair D, Melancon D, Richardson J, Leblanc R. Communicating hydrocephalus and vestibular schwannomas: etiology, treatment, and long-term follow-up. *J Neurol Surg B Skull Base*. 2013 Apr;74(2):68-74. doi: 10.1055/s-0033-1333621.
2. Rassouli A, Saliba J, Castano R, **Hier M, Zeitouni AG**. Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma. *Head Neck*. 2013 Dec 13. doi: 10.1002/hed.23567. [Epub ahead of print]
3. Cardin MJ, Fiset PO, **Zeitouni AG**, Caglar D. Ectomesenchymal Chondromyxoid Tumour of the Posterior Tongue. *Head Neck Pathol*. 2013 Nov 28. [Epub ahead of print]
4. Sibindi TM, Krasovsky T, Feldman AG, Dannenbaum E, **Zeitouni A**, Levin MF. Arm-trunk coordination as a measure of vestibulospinal efficiency. *J Vestib Res*. 2013;23(4-5):237-47. doi: 10.3233/VES-130485.
5. **Henry M**, Habib LA, Morrison M, Yang JW, Li XJ, Lin S, **Zeitouni A**, Payne R, Macdonald C, Mlynarek A, Kost K, **Black M, Hier M**. Head and neck cancer patients want us to support them psychologically in the posttreatment period: Survey results. *Palliat Support Care*. 2013 Oct 24:1-13. [Epub ahead of print]
6. D'Souza V, Blouin E, **Zeitouni A**, Muller K, Allison PJ. Do multimedia based information services increase knowledge and satisfaction in head and neck cancer patients? *Oral Oncol*. 2013 Sep;49(9):943-9. doi: 10.1016/j.oraloncology.2013.06.005. Epub 2013 Jul 16.

**Department of Oncology
2013 Publications**

7. Kleber B, **Zeitouni AG**, Friberg A, Zatorre RJ. Experience-dependent modulation of feedback integration during singing: role of the right anterior insula. *J Neurosci.* 2013 Apr 3;33(14):6070-80. doi: 10.1523/JNEUROSCI.4418-12.2013.